Account-creators
1,040
edits
Difference between revisions of "Molecular pathology tests"
Jump to navigation
Jump to search
→Neuropathology: wikify
Jensflorian (talk | contribs) (→Neuropathology: wikify) |
|||
| (8 intermediate revisions by 2 users not shown) | |||
| Line 141: | Line 141: | ||
| | | | ||
|- | |- | ||
| KRAS, BRAF | | [[KRAS mutation|KRAS]], BRAF | ||
| fluorescent RFLP, real time PCR, sequencing | | fluorescent RFLP, real time PCR, sequencing | ||
| metastatic [[colorectal carcinoma]] | | metastatic [[colorectal carcinoma]] | ||
| Line 151: | Line 151: | ||
| | | | ||
|- | |- | ||
| BRAF V600E | | [[BRAF V600E]] | ||
| ARMS | | ARMS | ||
| [[papillary thyroid carcinoma]] | | [[papillary thyroid carcinoma]] | ||
| Line 157: | Line 157: | ||
|} | |} | ||
=== | ===[[Neuropathology]]=== | ||
Common tests in neurooncology practice: | |||
{| class="wikitable sortable" style="margin-left:auto;margin-right:auto" | {| class="wikitable sortable" style="margin-left:auto;margin-right:auto" | ||
! Target | ! Target | ||
| Line 165: | Line 165: | ||
! Notes | ! Notes | ||
|- | |- | ||
| LOH 1p | | LOH 1p/19q | ||
| PCR | | PCR | ||
| [[oligodendroglioma]] | | [[oligodendroglioma]] | ||
| | | Prognostic and predicts response to PCV treatment.<ref>{{Cite journal | last1 = Cairncross | first1 = G. | last2 = Wang | first2 = M. | last3 = Shaw | first3 = E. | last4 = Jenkins | first4 = R. | last5 = Brachman | first5 = D. | last6 = Buckner | first6 = J. | last7 = Fink | first7 = K. | last8 = Souhami | first8 = L. | last9 = Laperriere | first9 = N. | title = Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. | journal = J Clin Oncol | volume = 31 | issue = 3 | pages = 337-43 | month = Jan | year = 2013 | doi = 10.1200/JCO.2012.43.2674 | PMID = 23071247 }}</ref> | ||
|- | |||
| [[IDH_mutation|IDH1/2]] | |||
| PCR + [[IDH-1|IDH1 R132H antibody]]. | |||
| [[oligodendroglioma]] & [[astrocytoma]]. | |||
| Diagnostic and prognostic.<ref>{{Cite journal | last1 = Hartmann | first1 = C. | last2 = Hentschel | first2 = B. | last3 = Wick | first3 = W. | last4 = Capper | first4 = D. | last5 = Felsberg | first5 = J. | last6 = Simon | first6 = M. | last7 = Westphal | first7 = M. | last8 = Schackert | first8 = G. | last9 = Meyermann | first9 = R. | title = Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. | journal = Acta Neuropathol | volume = 120 | issue = 6 | pages = 707-18 | month = Dec | year = 2010 | doi = 10.1007/s00401-010-0781-z | PMID = 21088844 }}</ref> | |||
|- | |||
| H3F3A | |||
| PCR + [[H3F3A|H3.3 K27M antibody]]. | |||
| [[glioblastoma]] & [[astrocytoma]]. | |||
| Diagnostic (K27M-mutant glioma of the midline / pediatric glioblastoma). <ref>{{Cite journal | last1 = Sturm | first1 = D. | last2 = Witt | first2 = H. | last3 = Hovestadt | first3 = V. | last4 = Khuong-Quang | first4 = DA. | last5 = Jones | first5 = DT. | last6 = Konermann | first6 = C. | last7 = Pfaff | first7 = E. | last8 = Tönjes | first8 = M. | last9 = Sill | first9 = M. | title = Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. | journal = Cancer Cell | volume = 22 | issue = 4 | pages = 425-37 | month = Oct | year = 2012 | doi = 10.1016/j.ccr.2012.08.024 | PMID = 23079654 }}</ref> | |||
|- | |||
| [[MGMT]] | |||
| Methylation-specific PCR, Pyroseq. | |||
| [[glioblastoma]], [[astrocytoma]] & [[oligodendroglioma]]. | |||
| Prognostic & predicts treatment to Temozolomide treatment.<ref>{{Cite journal | last1 = Stupp | first1 = R. | last2 = Hegi | first2 = ME. | last3 = Mason | first3 = WP. | last4 = van den Bent | first4 = MJ. | last5 = Taphoorn | first5 = MJ. | last6 = Janzer | first6 = RC. | last7 = Ludwin | first7 = SK. | last8 = Allgeier | first8 = A. | last9 = Fisher | first9 = B. | title = Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. | journal = Lancet Oncol | volume = 10 | issue = 5 | pages = 459-66 | month = May | year = 2009 | doi = 10.1016/S1470-2045(09)70025-7 | PMID = 19269895 }}</ref> | |||
|- | |||
| BRAF-Fusion | |||
| RT-PCR, RNAseq + Defuse-Analysis<ref>{{Cite journal | last1 = McPherson | first1 = A. | last2 = Hormozdiari | first2 = F. | last3 = Zayed | first3 = A. | last4 = Giuliany | first4 = R. | last5 = Ha | first5 = G. | last6 = Sun | first6 = MG. | last7 = Griffith | first7 = M. | last8 = Heravi Moussavi | first8 = A. | last9 = Senz | first9 = J. | title = deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. | journal = PLoS Comput Biol | volume = 7 | issue = 5 | pages = e1001138 | month = May | year = 2011 | doi = 10.1371/journal.pcbi.1001138 | PMID = 21625565 }}</ref> | |||
| [[pilocytic astrocytoma]] | |||
| Diagnostic.<ref>{{Cite journal | last1 = Hasselblatt | first1 = M. | last2 = Riesmeier | first2 = B. | last3 = Lechtape | first3 = B. | last4 = Brentrup | first4 = A. | last5 = Stummer | first5 = W. | last6 = Albert | first6 = FK. | last7 = Sepehrnia | first7 = A. | last8 = Ebel | first8 = H. | last9 = Gerss | first9 = J. | title = BRAF-KIAA1549 fusion transcripts are less frequent in pilocytic astrocytomas diagnosed in adults. | journal = Neuropathol Appl Neurobiol | volume = 37 | issue = 7 | pages = 803-6 | month = Dec | year = 2011 | doi = 10.1111/j.1365-2990.2011.01193.x | PMID = 21696415 }}</ref> | |||
|- | |||
| Rela-Fusion | |||
| RT-PCR, RNAseq + Defuse-Analysis | |||
| supratentorial [[ependymoma]] | |||
| Diagnostic and prognostic (unfavourable, when present).<ref>{{Cite journal | last1 = Parker | first1 = M. | last2 = Mohankumar | first2 = KM. | last3 = Punchihewa | first3 = C. | last4 = Weinlich | first4 = R. | last5 = Dalton | first5 = JD. | last6 = Li | first6 = Y. | last7 = Lee | first7 = R. | last8 = Tatevossian | first8 = RG. | last9 = Phoenix | first9 = TN. | title = C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. | journal = Nature | volume = 506 | issue = 7489 | pages = 451-5 | month = Feb | year = 2014 | doi = 10.1038/nature13109 | PMID = 24553141 }}</ref> | |||
|} | |||
===Other=== | |||
Tests for miscellaneous things:<ref name=uhn_molecular_tests>University Health Network. Molecular diagnostics - current testing. Document number: PMD10002. Version 2.0. March 30, 2011.</ref> | |||
{| class="wikitable sortable" style="margin-left:auto;margin-right:auto" | |||
! Target | |||
! Technique | |||
! Disease | |||
! Notes | |||
|- | |- | ||
| 15 STRs and amelogenin (XY) loci | |||
| PCR<ref>{{Cite journal | last1 = Romsos | first1 = EL. | last2 = Vallone | first2 = PM. | title = Rapid PCR of STR markers: Applications to human identification. | journal = Forensic Sci Int Genet | volume = | issue = | pages = | month = Apr | year = 2015 | doi = 10.1016/j.fsigen.2015.04.008 | PMID = 25937291 }}</ref> | |||
| | | | ||
| | | [[identity testing]] - chimerism analysis (post-[[BMT]]),<ref>{{Cite journal | last1 = Borrill | first1 = V. | last2 = Schlaphoff | first2 = T. | last3 = du Toit | first3 = E. | last4 = Marx | first4 = M. | last5 = Wood | first5 = L. | last6 = Jacobs | first6 = P. | title = The use of short tandem repeat polymorphisms for monitoring chimerism following bone marrow transplantation: a short report. | journal = Hematology | volume = 13 | issue = 4 | pages = 210-4 | month = Aug | year = 2008 | doi = 10.1179/102453308X316059 | PMID = 18796246 }}</ref> specimen mix-ups, [[decendent identification]]/evidence ([[forensic pathology]]) | ||
| | |||
| | |||
|- | |- | ||
| KIT, BRAF | | KIT, BRAF | ||